Lab Tested
99% Purity
USA Made
Sterile Fill
Triple agonist peptide targeting GLP-1, GIP, and Glucagon receptors simultaneously. The most potent weight-loss peptide in clinical trials. 99% purity.
Strictly for laboratory research use only. Not for human consumption.
Triple agonist peptide targeting GLP-1, GIP, and Glucagon receptors simultaneously. The most potent weight-loss peptide in clinical trials. 99% purity. Synthesized in a cGMP facility with stringent quality controls.
Retatrutide (LY-3437943) is a synthetic triple-agonist peptide that simultaneously engages three metabolically relevant G-protein-coupled receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. This tri-agonist design represents a novel approach in metabolic peptide research, extending beyond the dual-agonist paradigm.
Clinical-stage research has investigated retatrutide's multi-receptor pharmacology in metabolic studies. The GLP-1 receptor component has been studied for effects on insulin secretion and gastric motility. The GIP receptor engagement is under investigation for potential synergistic incretin effects. The glucagon receptor activation has been examined for its role in hepatic lipid metabolism, energy expenditure modulation, and thermogenesis. Phase 2 clinical trial data have been published examining this triple-agonist approach in metabolic research contexts.
The proposed mechanism involves simultaneous activation of cAMP signaling through three distinct receptor populations, potentially producing complementary metabolic effects: GLP-1R-mediated satiety signaling, GIPR-mediated incretin amplification, and glucagon receptor-mediated hepatic energy substrate mobilization and thermogenic activation.
Viking Labs synthesizes research-grade retatrutide at a USA-based cGMP facility with rigorous quality controls. Third-party HPLC analysis confirms 99%+ purity on every batch. Certificate of Analysis and batch serialization included. Sterile fill under aseptic conditions.
Storage: Store lyophilized peptide at -20C. Reconstituted at 2-8C, use within 28 days. Protect from light.
For laboratory research use only. Not for human consumption.
From exendin-4 to retatrutide — the complete history and future of GLP-1 receptor agonists in obesity, diabetes, cardiovascular, and neurological research.
14 min readMetabolic PeptidesHow the first dual incretin agonist achieved unprecedented weight loss and glycemic outcomes in the SURMOUNT and SURPASS clinical programs.
14 min read